Mid-Cycle Review Complete + Capital Raise
Botanix has today released an update regarding the progress of its lead product, Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis – a medical condition where excessive sweating occurs beyond what is needed to maintain normal body temperature. The U.S. Food and Drug Administration (FDA) has now conducted the mid-cycle review meeting for Sofpironium […]